Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Non-Current Liabilities (2016 - 2025)

Celldex Therapeutics has reported Other Non-Current Liabilities over the past 16 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $4.0 million for Q4 2025, up 16.41% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (up 16.41% YoY), and the annual figure for FY2025 was $4.0 million, up 16.41%.
  • Other Non-Current Liabilities for Q4 2025 was $4.0 million at Celldex Therapeutics, up from $2.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CLDX hit a ceiling of $10.5 million in Q1 2022 and a floor of $2.5 million in Q1 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $4.4 million (2023), compared with a mean of $4.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 60.93% in 2021 and later soared 71.14% in 2022.
  • Celldex Therapeutics' Other Non-Current Liabilities stood at $7.4 million in 2021, then decreased by 27.48% to $5.3 million in 2022, then decreased by 17.44% to $4.4 million in 2023, then fell by 21.12% to $3.5 million in 2024, then increased by 16.41% to $4.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $4.0 million (Q4 2025), $2.5 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.